array(40) {
  [0]=>
  string(4) "1734"
  ["article_id"]=>
  string(4) "1734"
  [1]=>
  string(60) "Are we dispensing too many multicompartment compliance aids?"
  ["article_title"]=>
  string(60) "Are we dispensing too many multicompartment compliance aids?"
  [2]=>
  string(150) "Millions of multicompartment compliance aids (MCAs) are handed out by pharmacists each year, but evidence for their benefits is hard to find. Few pati"
  ["short_description"]=>
  string(150) "Millions of multicompartment compliance aids (MCAs) are handed out by pharmacists each year, but evidence for their benefits is hard to find. Few pati"
  [3]=>
  string(252) "Millions of multicompartment compliance aids (MCAs) are handed out by pharmacists each year, but evidence for their benefits is hard to find. Few patients are assessed before being given an MCA and concerns are building over potential errors and harms."
  ["description"]=>
  string(252) "Millions of multicompartment compliance aids (MCAs) are handed out by pharmacists each year, but evidence for their benefits is hard to find. Few patients are assessed before being given an MCA and concerns are building over potential errors and harms."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(142) "https://www.pharmaceutical-journal.com/news-and-analysis/features/are-we-dispensing-too-many-multicompartment-compliance-aids/20206131.article"
  ["blog_url"]=>
  string(142) "https://www.pharmaceutical-journal.com/news-and-analysis/features/are-we-dispensing-too-many-multicompartment-compliance-aids/20206131.article"
  [15]=>
  string(19) "2019-02-08 22:59:00"
  ["add_date"]=>
  string(19) "2019-02-08 22:59:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:37"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2408"
  ["article_id"]=>
  string(4) "2408"
  [1]=>
  string(135) "New Brexit Q&A provides several examples in relation to the “placing on the EU market”of products including medical devices"
  ["article_title"]=>
  string(135) "New Brexit Q&A provides several examples in relation to the “placing on the EU market”of products including medical devices"
  [2]=>
  string(150) "On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the "
  ["short_description"]=>
  string(150) "On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the "
  [3]=>
  string(748) "
On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the United Kingdom and EU rules in the field of industrial products (“the Notice”). This Notice applies, among others, to medical devices, active implantable medical devices and in vitro medical devices. The Q&A
&#nl
The post New Brexit Q&A provides several examples in relation to the “placing on the EU market”of products including medical devices appeared first on Focus on Regulation.
&#nl"
  ["description"]=>
  string(748) "
On 1 February 2019, the European Commission published a new Q&A document to give further guidance on the Notice to stakeholders-withdrawal of the United Kingdom and EU rules in the field of industrial products (“the Notice”). This Notice applies, among others, to medical devices, active implantable medical devices and in vitro medical devices. The Q&A
&#nl
The post New Brexit Q&A provides several examples in relation to the “placing on the EU market”of products including medical devices appeared first on Focus on Regulation.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "101"
  ["rss_id"]=>
  string(3) "101"
  [14]=>
  string(46) "https://www.hlregulation.com/2019/02/06/11032/"
  ["blog_url"]=>
  string(46) "https://www.hlregulation.com/2019/02/06/11032/"
  [15]=>
  string(19) "2019-02-07 01:17:44"
  ["add_date"]=>
  string(19) "2019-02-07 01:17:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:28"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1712"
  ["article_id"]=>
  string(4) "1712"
  [1]=>
  string(121) "Zogenix Submits New Drug Application to U.S. Food & Drug Administration for Fintepla for the Treatment of Dravet Syndrome"
  ["article_title"]=>
  string(121) "Zogenix Submits New Drug Application to U.S. Food & Drug Administration for Fintepla for the Treatment of Dravet Syndrome"
  [2]=>
  string(150) "EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, "
  ["short_description"]=>
  string(150) "EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, "
  [3]=>
  string(252) "EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S...."
  ["description"]=>
  string(252) "EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S...."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(213) "https://www.drugs.com/nda/fintepla_190206.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zogenix+Submits+New+Drug+Application+to+U.S.+Food+%26+Drug+Administration+for+Fintepla+for+the+Treatment+of+Dravet+Syndrome"
  ["blog_url"]=>
  string(213) "https://www.drugs.com/nda/fintepla_190206.html?utm_source=ddc&utm_medium=rss&utm_campaign=Zogenix+Submits+New+Drug+Application+to+U.S.+Food+%26+Drug+Administration+for+Fintepla+for+the+Treatment+of+Dravet+Syndrome"
  [15]=>
  string(19) "2019-02-06 11:02:00"
  ["add_date"]=>
  string(19) "2019-02-06 11:02:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5293"
  ["article_id"]=>
  string(4) "5293"
  [1]=>
  string(62) "14th Annual Conference on Dementia and Alzheimer's Disease"
  ["article_title"]=>
  string(62) "14th Annual Conference on Dementia and Alzheimer's Disease"
  [2]=>
  string(150) "Dementia Conference 2019 welcomes you to grace with your presence. 14th Annual Conference on Dementia and Alzheimer's Disease to be held in Johann"
  ["short_description"]=>
  string(150) "Dementia Conference 2019 welcomes you to grace with your presence. 14th Annual Conference on Dementia and Alzheimer's Disease to be held in Johann"
  [3]=>
  string(514) "Dementia Conference 2019 welcomes you to grace with your presence. 14th Annual Conference on Dementia and Alzheimer's Disease to be held in Johannesburg, South Africa during November 18-19, 2019. This Dementia2019 Conference will bring University professors, Neuro Psychologists, Neuro Chemist, Neurophysiologist, Neurosurgeons, Neurology organization & societies, Neuromuscular Specialist, Pharmacists, Pharmaceutical companies globally with the theme of “A Global Forum to Advance Dementia S..."
  ["description"]=>
  string(514) "Dementia Conference 2019 welcomes you to grace with your presence. 14th Annual Conference on Dementia and Alzheimer's Disease to be held in Johannesburg, South Africa during November 18-19, 2019. This Dementia2019 Conference will bring University professors, Neuro Psychologists, Neuro Chemist, Neurophysiologist, Neurosurgeons, Neurology organization & societies, Neuromuscular Specialist, Pharmacists, Pharmaceutical companies globally with the theme of “A Global Forum to Advance Dementia S..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(89) "https://www.pharmiweb.com/event/14th-annual-conference-on-dementia-and-alzheimers-disease"
  ["blog_url"]=>
  string(89) "https://www.pharmiweb.com/event/14th-annual-conference-on-dementia-and-alzheimers-disease"
  [15]=>
  string(19) "2019-02-06 10:59:54"
  ["add_date"]=>
  string(19) "2019-02-06 10:59:54"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1746"
  ["article_id"]=>
  string(4) "1746"
  [1]=>
  string(116) "Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia"
  ["article_title"]=>
  string(116) "Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia"
  [2]=>
  string(150) "CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical c"
  ["short_description"]=>
  string(150) "CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical c"
  [3]=>
  string(243) "CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through..."
  ["description"]=>
  string(243) "CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(283) "https://www.drugs.com/clinical_trials/apellis-apl-2-receives-orphan-designation-fda-autoimmune-hemolytic-anemia-18073.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apellis%E2%80%99+APL-2+Receives+Orphan+Drug+Designation+from+the+FDA+for+the+Treatment+of+Autoimmune+Hemolytic+Anemia"
  ["blog_url"]=>
  string(283) "https://www.drugs.com/clinical_trials/apellis-apl-2-receives-orphan-designation-fda-autoimmune-hemolytic-anemia-18073.html?utm_source=ddc&utm_medium=rss&utm_campaign=Apellis%E2%80%99+APL-2+Receives+Orphan+Drug+Designation+from+the+FDA+for+the+Treatment+of+Autoimmune+Hemolytic+Anemia"
  [15]=>
  string(19) "2019-02-06 06:02:12"
  ["add_date"]=>
  string(19) "2019-02-06 06:02:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2387"
  ["article_id"]=>
  string(4) "2387"
  [1]=>
  string(78) "MDSAP Aims to Unifiy Standards for Auditing Medical Device Manufacturing Lines"
  ["article_title"]=>
  string(78) "MDSAP Aims to Unifiy Standards for Auditing Medical Device Manufacturing Lines"
  [2]=>
  string(153) "&#nl        For medical device manufacturing, quality is crucial. To ensure quality in production, audits of the manufacturing facilities by a government"
  ["short_description"]=>
  string(153) "&#nl        For medical device manufacturing, quality is crucial. To ensure quality in production, audits of the manufacturing facilities by a government"
  [3]=>
  string(345) "&#nl        For medical device manufacturing, quality is crucial. To ensure quality in production, audits of the manufacturing facilities by a government health organization are standard. The audits and inspections are not, however, standard between countries. The Medical Device Single Audit Program (MDSAP) is looking to change that.&#nl      "
  ["description"]=>
  string(345) "&#nl        For medical device manufacturing, quality is crucial. To ensure quality in production, audits of the manufacturing facilities by a government health organization are standard. The audits and inspections are not, however, standard between countries. The Medical Device Single Audit Program (MDSAP) is looking to change that.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "99"
  ["rss_id"]=>
  string(2) "99"
  [14]=>
  string(121) "https://www.assemblymag.com/articles/94743-mdsap-aims-to-unifiy-standards-for-auditing-medical-device-manufacturing-lines"
  ["blog_url"]=>
  string(121) "https://www.assemblymag.com/articles/94743-mdsap-aims-to-unifiy-standards-for-auditing-medical-device-manufacturing-lines"
  [15]=>
  string(19) "2019-02-06 00:10:00"
  ["add_date"]=>
  string(19) "2019-02-06 00:10:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:22"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:22"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1735"
  ["article_id"]=>
  string(4) "1735"
  [1]=>
  string(61) "Prevention of venous thromboembolism in hospitalised patients"
  ["article_title"]=>
  string(61) "Prevention of venous thromboembolism in hospitalised patients"
  [2]=>
  string(155) "Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a r"
  ["short_description"]=>
  string(155) "Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a r"
  [3]=>
  string(191) "Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a range of hospitalised patient groups."
  ["description"]=>
  string(191) "Pharmacists should note the National Institute for Health and Care Excellence’s updated guidance on use of pharmacological thromboprophylaxis in a range of hospitalised patient groups."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(138) "https://www.pharmaceutical-journal.com/learning/cpd-article/prevention-of-venous-thromboembolism-in-hospitalised-patients/20206037.article"
  ["blog_url"]=>
  string(138) "https://www.pharmaceutical-journal.com/learning/cpd-article/prevention-of-venous-thromboembolism-in-hospitalised-patients/20206037.article"
  [15]=>
  string(19) "2019-02-05 23:31:00"
  ["add_date"]=>
  string(19) "2019-02-05 23:31:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:37"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5256"
  ["article_id"]=>
  string(4) "5256"
  [1]=>
  string(57) "euroPLX 71 Lisbon (Portugal) Pharma Partnering Conference"
  ["article_title"]=>
  string(57) "euroPLX 71 Lisbon (Portugal) Pharma Partnering Conference"
  [2]=>
  string(150) "The 71st euroPLX Pharma Partnering Conference will be held in Cascais, a picturesque town, located about 25-30 driving minutes from Lisbon. euroPLX 71"
  ["short_description"]=>
  string(150) "The 71st euroPLX Pharma Partnering Conference will be held in Cascais, a picturesque town, located about 25-30 driving minutes from Lisbon. euroPLX 71"
  [3]=>
  string(506) "The 71st euroPLX Pharma Partnering Conference will be held in Cascais, a picturesque town, located about 25-30 driving minutes from Lisbon. euroPLX 71 Lisbon is expected to see 350 to 400 top level business development executives from all over the world.&#nl&#nlThe online interaction and matchmaking systems of euroPLX Conferences provide 25 to 30 pre-arranged business meetings per attending company. It is the preferred partnering platform for new business opportunities since 24 years. Information e..."
  ["description"]=>
  string(506) "The 71st euroPLX Pharma Partnering Conference will be held in Cascais, a picturesque town, located about 25-30 driving minutes from Lisbon. euroPLX 71 Lisbon is expected to see 350 to 400 top level business development executives from all over the world.&#nl&#nlThe online interaction and matchmaking systems of euroPLX Conferences provide 25 to 30 pre-arranged business meetings per attending company. It is the preferred partnering platform for new business opportunities since 24 years. Information e..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(87) "https://www.pharmiweb.com/event/europlx-71-lisbon-portugal-pharma-partnering-conference"
  ["blog_url"]=>
  string(87) "https://www.pharmiweb.com/event/europlx-71-lisbon-portugal-pharma-partnering-conference"
  [15]=>
  string(19) "2019-02-05 17:42:18"
  ["add_date"]=>
  string(19) "2019-02-05 17:42:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:27"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1851"
  ["article_id"]=>
  string(4) "1851"
  [1]=>
  string(168) "Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market"
  ["article_title"]=>
  string(168) "Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides to bring innovation to the largest baby food market"
  [2]=>
  string(150) "China represents the largest market for baby food globallyHuman milk oligosaccharides are key for the development of a healthy infant microbiomeHohhot"
  ["short_description"]=>
  string(150) "China represents the largest market for baby food globallyHuman milk oligosaccharides are key for the development of a healthy infant microbiomeHohhot"
  [3]=>
  string(572) "China represents the largest market for baby food globallyHuman milk oligosaccharides are key for the development of a healthy infant microbiomeHohhot, China & Rheinbreitbach, Germany – Jennewein Biotechnologie GmbH, the global leader in the research and manufacture of human milk oligosaccharides (HMO), and Inner Mongolia Yili Industrial Group (Yili Group), China’s leading dairy company, announce today the signing of a Memorandum of Understanding on infant microbiome and human milk oligosaccharides, with the goal to develop...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(572) "China represents the largest market for baby food globallyHuman milk oligosaccharides are key for the development of a healthy infant microbiomeHohhot, China & Rheinbreitbach, Germany – Jennewein Biotechnologie GmbH, the global leader in the research and manufacture of human milk oligosaccharides (HMO), and Inner Mongolia Yili Industrial Group (Yili Group), China’s leading dairy company, announce today the signing of a Memorandum of Understanding on infant microbiome and human milk oligosaccharides, with the goal to develop...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(93) "http://www.realwire.com/releases/Jennewein-Biotechnologie-and-Yili-Group-join-forces-in-China"
  ["blog_url"]=>
  string(93) "http://www.realwire.com/releases/Jennewein-Biotechnologie-and-Yili-Group-join-forces-in-China"
  [15]=>
  string(19) "2019-02-05 16:00:00"
  ["add_date"]=>
  string(19) "2019-02-05 16:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1713"
  ["article_id"]=>
  string(4) "1713"
  [1]=>
  string(75) "Pain Therapeutics Announces Feedback from Recent Meeting With FDA on Remoxy"
  ["article_title"]=>
  string(75) "Pain Therapeutics Announces Feedback from Recent Meeting With FDA on Remoxy"
  [2]=>
  string(150) "AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced fe"
  ["short_description"]=>
  string(150) "AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced fe"
  [3]=>
  string(245) "AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA)..."
  ["description"]=>
  string(245) "AUSTIN, Texas, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a clinical-stage drug development company, today announced feedback from a meeting held January 31, 2019 with the U.S. Food and Drug Administration (FDA)..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(166) "https://www.drugs.com/nda/remoxy_er_190205.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pain+Therapeutics+Announces+Feedback+from+Recent+Meeting+With+FDA+on+Remoxy"
  ["blog_url"]=>
  string(166) "https://www.drugs.com/nda/remoxy_er_190205.html?utm_source=ddc&utm_medium=rss&utm_campaign=Pain+Therapeutics+Announces+Feedback+from+Recent+Meeting+With+FDA+on+Remoxy"
  [15]=>
  string(19) "2019-02-05 11:02:27"
  ["add_date"]=>
  string(19) "2019-02-05 11:02:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1736"
  ["article_id"]=>
  string(4) "1736"
  [1]=>
  string(56) "Marie-Anne Durham: coffee, ethics and David Attenborough"
  ["article_title"]=>
  string(56) "Marie-Anne Durham: coffee, ethics and David Attenborough"
  [2]=>
  string(104) "Spend a minute getting to know the winner of the 2018 Scottish Pharmacy Awards Student Leadership Prize."
  ["short_description"]=>
  string(104) "Spend a minute getting to know the winner of the 2018 Scottish Pharmacy Awards Student Leadership Prize."
  [3]=>
  string(104) "Spend a minute getting to know the winner of the 2018 Scottish Pharmacy Awards Student Leadership Prize."
  ["description"]=>
  string(104) "Spend a minute getting to know the winner of the 2018 Scottish Pharmacy Awards Student Leadership Prize."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(154) "https://www.pharmaceutical-journal.com/careers-and-jobs/careers-and-jobs/career-qa/marie-anne-durham-coffee-ethics-and-david-attenborough/20206018.article"
  ["blog_url"]=>
  string(154) "https://www.pharmaceutical-journal.com/careers-and-jobs/careers-and-jobs/career-qa/marie-anne-durham-coffee-ethics-and-david-attenborough/20206018.article"
  [15]=>
  string(19) "2019-02-04 22:54:00"
  ["add_date"]=>
  string(19) "2019-02-04 22:54:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:37"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5307"
  ["article_id"]=>
  string(4) "5307"
  [1]=>
  string(66) "TIDES Europe: Oligonucleotide and Peptide Therapeutics | Amsterdam"
  ["article_title"]=>
  string(66) "TIDES Europe: Oligonucleotide and Peptide Therapeutics | Amsterdam"
  [2]=>
  string(156) "TIDES OFFERS THE SCIENCE, TECHNOLOGIES AND PARTNERS YOU NEED TO GROW YOUR BUSINESS&#nl&#nl>> 400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND E"
  ["short_description"]=>
  string(156) "TIDES OFFERS THE SCIENCE, TECHNOLOGIES AND PARTNERS YOU NEED TO GROW YOUR BUSINESS&#nl&#nl>> 400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND E"
  [3]=>
  string(534) "TIDES OFFERS THE SCIENCE, TECHNOLOGIES AND PARTNERS YOU NEED TO GROW YOUR BUSINESS&#nl&#nl>> 400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES&#nlFast-track your oligonucleotide and peptide research to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from North America, Asia and Europe.&#nl&#nl>>40+ CASE STUDIES AND NEW DATA PRESENTATIONS&#nlHear best practices, lessons learned and important industry developments across the entire spectr..."
  ["description"]=>
  string(534) "TIDES OFFERS THE SCIENCE, TECHNOLOGIES AND PARTNERS YOU NEED TO GROW YOUR BUSINESS&#nl&#nl>> 400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES&#nlFast-track your oligonucleotide and peptide research to the clinic and beyond by collaborating with leading pharma, biotechs, academia and solution providers from North America, Asia and Europe.&#nl&#nl>>40+ CASE STUDIES AND NEW DATA PRESENTATIONS&#nlHear best practices, lessons learned and important industry developments across the entire spectr..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(95) "https://www.pharmiweb.com/event/tides-europe-oligonucleotide-and-peptide-therapeutics-amsterdam"
  ["blog_url"]=>
  string(95) "https://www.pharmiweb.com/event/tides-europe-oligonucleotide-and-peptide-therapeutics-amsterdam"
  [15]=>
  string(19) "2019-02-04 20:07:25"
  ["add_date"]=>
  string(19) "2019-02-04 20:07:25"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}